There are 2137 resources available
1076O - Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238
Presenter: Jeffrey Weber
Session: Proffered Paper - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
LBA23 - Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361
Presenter: Ajjai Alva
Session: Proffered Paper - GU, non prostate 1
Resources:
Abstract
Slides
Webcast
697O - A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE)
Presenter: Thomas Powles
Session: Proffered Paper - GU, non prostate 1
Resources:
Abstract
Slides
Webcast
LBA24 - TROPHY-U-01 cohort 1 final results: A phase II study of sacituzumab govitecan (SG) in metastatic urothelial cancer (mUC) that has progressed after platinum (PLT) and checkpoint inhibitors (CPI)
Presenter: Yohann Loriot
Session: Proffered Paper - GU, non prostate 1
Resources:
Abstract
Slides
Webcast
698O - Patient-reported outcomes (PROs) from IMvigor130: A global, randomised, partially blinded phase III study of atezolizumab (atezo) + platinum-based chemotherapy (PBC) vs placebo (PBO) + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)
Presenter: Aristotelis Bamias
Session: Proffered Paper - GU, non prostate 1
Resources:
Abstract
Slides
Webcast
699O - Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC): Association between clinical outcomes and exploratory biomarkers
Presenter: Srikala Sridhar
Session: Proffered Paper - GU, non prostate 1
Resources:
Abstract
Slides
Webcast
LBA15 - Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)
Presenter: David Miles
Session: Proffered Paper - Breast cancer, metastatic 1
Resources:
Abstract
Slides
Webcast
LBA16 - IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer
Presenter: Leisha Emens
Session: Proffered Paper - Breast cancer, metastatic 1
Resources:
Abstract
Slides
Webcast
LBA17 - ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC)
Presenter: Aditya Bardia
Session: Proffered Paper - Breast cancer, metastatic 1
Resources:
Abstract
Slides
Webcast
LBA18 - Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP) + fulvestrant (FUL) for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC)
Presenter: Fabrice André
Session: Proffered Paper - Breast cancer, metastatic 1
Resources:
Abstract
Slides
Webcast